RescEU is part of the EU Civil Protection Mechanism, established by the European Commission as a safety net to protect citizens from disasters and manage emerging risks
MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic is a non-replicating smallpox and mpox vaccine. (Credit: Mathurin NAPOLY / matnapo on Unsplash)
Bavarian Nordic today announced the award of a contract valued at EUR 65 million to supply its MVA-BN smallpox vaccine to the strategic reserve within the European Union (EU) in 2025.
This third, and larger order follows two previous orders, received in 2023 and delivered in 2024, for smallpox vaccines to rescEU stockpiles across Europe and will help to expand the EU’s capability to respond to future biological threats and emergencies by enabling rapid deployment of medical countermeasures to its member states.
Paul Chaplin, President & CEO of Bavarian Nordic, said: “Public health crises in recent years have demonstrated the need for building a robust infrastructure across EU nations for deploying vaccines in emergencies. We applaud the rescEU initiative, which aims to reinforce the EU’s ability to respond to future health crises and through incremental orders for our smallpox vaccine will further strengthen the biological preparedness across the region. We are pleased to expand this collaboration, as we further increase our commitments to supplying smallpox vaccines to a growing customer base, while also adding to our base of secured contracts for 2025.”
Source: Company Press Release